---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-031210"
form_type: "8-K"
ticker: "GNPX"
cik: "0001595248"
company_name: "Genprex, Inc."
filed_at: "2025-10-17T23:59:59+00:00"
generated_at: "2026-05-17T03:23:42.324035+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "medium"
source: SEC EDGAR
---

# Genprex granted Nasdaq exception through Oct 31, 2025; 1-for-50 reverse stock split effective Oct 21

## Summary
- Nasdaq Panel exception to demonstrate compliance with $1.00 bid price and $2.5M stockholders' equity until Oct 31, 2025; Panel may extend to Feb 9, 2026.
- 1-for-50 reverse stock split filed Oct 16, effective Oct 21, 2025; CUSIP changes to 372446-302; symbol remains GNPX.
- Acclaim-1 (REQORSA + Tagrisso) Phase 2a enrollment ongoing; interim analysis of first 19 patients expected H2 2026.
- Acclaim-3 (REQORSA + Tecentriq) Phase 2 expansion enrolling; futility analysis after 25th patient expected H2 2026.
- Diabetes gene therapy GPX-002 in preclinical studies; plans to request FDA meeting for IND-enabling studies by end of 2025.

## SEC filing metadata
- accession: 0001437749-25-031210
- form_type: 8-K
- ticker: GNPX
- cik: 0001595248
- company_name: Genprex, Inc.
- filed_at: 2025-10-17T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: medium
- sec_items: 3.01, 3.03, 5.03, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595248/000143774925031210/0001437749-25-031210-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595248/000143774925031210/gnpx20251001_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-031210
- JSON: https://secwatch.observer/filing/0001437749-25-031210.json
- Plain text: https://secwatch.observer/filing/0001437749-25-031210.txt

## Source-grounded claims
- claim_id: 1d3b9ca4b8087f35be9b75eb76b6584255110772
  claim: Genprex, Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2), 5550(b)(1)).
  evidence_excerpt: August 12, 2025, the Company received a letter from Nasdaq indicating that, because the Company has not regained compliance with the Bid Price Requirement and because of the Company’s ineligibility for a second 180 calendar day compliance period, the Staff had determined to delist the Company’s securities from Nasdaq unless the Company timely requested a hearing with the Panel. The Company timely requested a hearing before the Panel, which was held on September 18, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1595248/000143774925031210/0001437749-25-031210-index.htm
- claim_id: 50cc24aac74dfda4772112233a837047c46d3599
  claim: Genprex, Inc. received a nasdaq deficiency notice notice regarding stockholders equity.
  evidence_excerpt: August 19, 2025, the Company received a notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, the Company was not in compliance with the Minimum Stockholders’ Equity Requirement and as previously disclosed, on August 12, 2025, the Company received a letter from Nasdaq indicating that, because the Company has not regained compliance with the Bid Price Requirement and because of the Company’s ineligibility for a second 180 calendar day compliance period, the Staff had determined to delist the Company’s securities from Nasdaq unless
  evidence_url: https://www.sec.gov/Archives/edgar/data/1595248/000143774925031210/0001437749-25-031210-index.htm
- claim_id: fa8706b5896184713653204b1ca8e47e54dfaac8
  claim: Genprex, Inc. received a nasdaq hearing update notice regarding minimum bid price.
  evidence_excerpt: received a notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, the Company was not in compliance with the Minimum Stockholders’ Equity Requirement and as previously disclosed, on August 12, 2025, the Company received a letter from Nasdaq indicating that, because the Company has not regained compliance with the Bid Price Requirement and because of the Company’s ineligibility for a second 180 calendar day compliance period, the Staff had determined to delist the Company’s securities from Nasdaq unless the Company timely requested
  evidence_url: https://www.sec.gov/Archives/edgar/data/1595248/000143774925031210/0001437749-25-031210-index.htm
- claim_id: 5724e42a3a5eb0b90ef3af4f69aba87840ac5116
  claim: Genprex, Inc.: Certificate of Amendment to effect a one-for-fifty reverse stock split (effective 2025-10-21).
  evidence_excerpt: On October 16, 2025, Genprex filed a Certificate of Amendment to the Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware (the “Certificate of Amendment”), which will effect, at 12:01 a.m. Eastern Time on October 21, 2025, a one-for-fifty (1:50) reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding shares of common stock, par value $0.001 per share (the “Common Stock”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1595248/000143774925031210/0001437749-25-031210-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.